Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220626 | 0.85 | AKR1C3 (0.45) | MMP2AKR1C3HSD11B1ESR1GLA | |
| SCHEMBL916742 | 0.83 | HSD11B1 (0.43) | MMP2HSD11B1ESR1ACHE | |
| SCHEMBL916819 | 0.83 | PSEN1 (0.57) | MMP2AKR1C3HSD11B1CTSGCMA1 | |
| SCHEMBL2221418 | 0.82 | ACHE (0.49) | MMP2AKR1C3HSD11B1ESR1ACHE | |
| SCHEMBL2221744 | 0.80 | ACHE (0.50) | MMP2AKR1C3ACHEMAPK1HTT | |
| SCHEMBL19332116 | 0.80 | PARL (0.53) | MMP2AKR1C3HSD11B1ACHE | |
| SCHEMBL12786686 | 0.79 | HSD11B1 (0.67) | HSD11B1ACHE | |
| SCHEMBL19332101 | 0.79 | MMP2 (0.46) | MMP2AKR1C3HSD11B1ESR1 | |
| SCHEMBL916558 | 0.77 | PSEN1 (0.62) | MMP2HSD11B1CTSGCMA1ACHE | |
| SCHEMBL917161 | 0.77 | ACHE (0.44) | AKR1C3HSD11B1ESR1ACHEMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | claimed |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1916985-A2 | BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007022502-A2 | BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | MMP2 2433/4885AKR1C3 1259/4885HSD11B1 534/4885 |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | MMP2 2109/4885AKR1C3 1470/4885HSD11B1 544/4885 |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | MMP2 2433/4885AKR1C3 1259/4885HSD11B1 534/4885 |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | MMP2 2433/4885AKR1C3 1259/4885HSD11B1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.